Cargando…
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises. Several vaccine approaches and repurposed drugs are currently under evaluation for safety and efficacy. However, none of them have been approved for COVID-19 yet. Meanwhile, several nMAbs targeting SARS-CoV-2 spike g...
Autor principal: | Jaworski, Juan Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685954/ https://www.ncbi.nlm.nih.gov/pubmed/33589377 http://dx.doi.org/10.1016/j.bj.2020.11.011 |
Ejemplares similares
-
Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021) -
Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
por: Jaworski, Juan Pablo, et al.
Publicado: (2017) -
Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021) -
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
por: de Almeida Oliveira, Aline, et al.
Publicado: (2023) -
Neutralizing antibodies for the prevention and treatment of COVID-19
por: Du, Lanying, et al.
Publicado: (2021)